Neurodevelopment Biotech PaxMedica To Debut On NASDAQ Tomorrow
PaxMedica Inc, a Phase 2 biotech developing therapies for neurodevelopmental disorders, revived its IPO plans to raise up to $9…
Surgalign Scores FDA Approval For New Flagship Posterior Fixation Platform
Surgalign Holdings Inc (NASDAQ:SRGA) announced FDA 510(k) clearance of the Cortera Spinal Fixation System, a key piece to the foundational portfolio…
SELLAS Life Sciences Touts Encouraging Preclinical Data For Candidate For Aggressive Form Of Prostate Cancer
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced results from a new preclinical in vitro study for its highly selective…
Pieris Pharma Shares Pop On Preclinical Data From Potential Lung Disease Candidate
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced the presentation of preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein for muco-obstructive lung diseases,…
Glaukos Inks Licensing Pact For Rare Eye Disorder Treatment
iVeena Delivery Systems Inc has entered into a strategic licensing agreement with Glaukos Corporation (NYSE:GKOS), granting an exclusive global license to develop and…
Petco Health Disappoints With Smaller Than Expected Q2 Profits, Annual Guidance
Petco Health And Wellness Company Inc’s (NASDAQ:WOOF) Q2 sales increased 3.2% Y/Y to $1.48 billion, missing the consensus of $1.49…
Integra LifeSciences Recalls CereLink Intracranial Pressure Monitors, Revises Guidance
Integra LifeSciences Holdings Corporation (NASDAQ:IART) initiated an immediate voluntary removal of all CereLink intracranial pressure monitors after customer reports about monitors…
EXCLUSIVE: Pressure BioSciences Inks Cosmeceuticals Partnership Using Nano Emulsification Platform
Pressure BioSciences Inc (OTC: PBIO) has teamed up with Dr. Adrienne Denese for a two-year Collaborative Research and Development Agreement.
Boxed Warnings May Not Hinder This Depression Drug’s Broad Market Penetration, Analyst Says
Last week, Axsome Therapeutics Inc’s (NASDAQ:AXSM) major depression candidate received the much-awaited FDA approval. HC Wainwright notes that the approval comes roughly…
Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why
Mizuho updated the price target for Cerevel Therapeutics Holdings Inc (NASDAQ:CERE) from $27 to $32 keeping the Neutral rating. The updated model…